October 14th
Neuromod has spent years conducting clinical trials to determine the efficacy of its Lenire bimodal stimulation device to reduce tinnitus symptoms. Results of the first of two large-scale clinical trials (TENT-A1), which included 326 participants across two European clinical sites (Dublin, Ireland and Regensburg, Germany), over a 15 months period, were released today. Note that Neuromod is currently seeking FDA approval so the device is not yet available on the US market. To learn more, click here to read the article.
